COA minimums documented across their product pages are 98%
Loargys : Immedica advances enzyme replacement for ARG1-D under accelerated approval Loargys On February 23, Immedica Pharma secured accelerated approval for Loargys (pegzilarginase-nbln) injection for hyperargininemia in adults and pediatric patients aged 2 years and older with arginase 1 deficiency, in conjunction with dietary protein restriction
In APP/PS1 transgenic mice, (D-Ser2)Oxm, a dual GLP-1 and Gcg receptor agonist, notably improves spatial memory and synaptic plasticity, reduces A plaque deposition in the hippocampus, and modulates the PI3K/AKT1/GSK3 signaling pathway [84]
Sun C, Lv T, Huang L, Liu X, Jin C, Lin X
Both boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
Dynamin 2-dependent endocytosis sustains T-cell receptor signaling and drives metabolic reprogramming in T lymphocytes